Results
|
1.
|
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. MedStar authors:
Year: 2019
Citation: - Diabetes Care. 42(9):1724-1732, 2019 09.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Altuntas Y, Aroda VR, Christiansen E, Haluzik M, Hertz CL, Jeppesen OK, Lalic NM, Morales Villegas EC, PIONEER 1 Investigators, Rosenstock J, Terauchi Y
|
|
2.
|
|
|
3.
|
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. MedStar authors:
Year: 2019
Citation: - Diabetes Care. 42(12):2262-2271, 2019 12.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Araki E, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, PIONEER 8 investigators, Tarp-Johansen MJ, Zinman B
|
|
4.
|
|
|
5.
|
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. MedStar authors:
Year: 2018
Citation: - New England Journal of Medicine. 379(12):1107-1117, 2018 09 20.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Bohula EA, Bonaca MP, Brown C, Budaj A, CAMELLIA-TIMI 61 Steering Committee and Investigators, Dhadda S, Fanola CL, Francis B, Garcia-Castillo A, Gupta M, Im K, Inzucchi SE, Keech AC, Kuder J, Leiter LA, McGuire DK, Miao W, Patel T, Perdomo C, Qamar A, Ruff CT, Sabatine MS, Scirica BM, Smith SR, Weissman NJ, White HD, Wiviott SD
|
|
6.
|
|
|
7.
|
Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. MedStar authors:
Year: 2020
Citation: - Diabetes Care. 43(5):940-947, 2020 05.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Butera NM, Camp AW, Cherrington A, Craig J, Fortmann SP, GRADE Research Group, Hollander PA, Krakoff J, Perez M, Phillips LS, Rasouli N, Sivitz WI, Tan MH, Tiktin M, Wexler DJ, Younes N
|
|
8.
|
|
|
9.
|
Neuropsychiatric safety with liraglutide 3.0mg for weight management: results from randomized controlled phase 2 and 3a trials. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(11):1529-1536, 2017 Nov.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Astrup A, Brett J, Cancino A, Kushner R, Lau DC, O'Neil PM, Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups, Wadden TA, Wilding JP
|